Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Septerna, Inc.

SEPNNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 13, 2026Accepted Nov 13, 2026, 7:02 PM ESTFiling CIK 1984086Accession 0001193125-26-461248
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-11-11
Issuer
Septerna, Inc.
Issuer CIK
0001984086
Trading symbol
SEPN
Rule 10b5-1 indication
Checked

Reporting owner 1

Name
Ezekowitz Alan
Reporting owner CIK
0001780209
Relationship
Director
Address
C/O SEPTERNA, INC., 250 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080

Non-derivative transactions

Non-derivative transactions · 7 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-11-11S · Form 4[F1]6,939D46.005[F2]110,481D
Common Stock2026-11-11S · Form 4[F1]13,201D47.0116[F3]97,280D
Common Stock2026-11-11S · Form 4[F1]22,865D47.7799[F4]74,415D
Common Stock2026-11-11S · Form 4[F1]31,572D48.7002[F5]42,843D
Common Stock2026-11-11S · Form 4[F1]4,175D49.6465[F6]38,668D
Common Stock2026-11-11S · Form 4[F1]2,013D50.897[F7]36,655D
Common Stock2026-11-11S · Form 4[F1]1,055D51.935,600D
Table key
S · Form 4
Sale on the market or privately
D
Direct

Footnotes

F1
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7
F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.36 to $46.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.37 to $47.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.37 to $48.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.37 to $49.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
F6
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.38 to $50.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
F7
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.47 to $51.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1

Signature 1

Signed
/s/ Mark A. Wilson, Attorney-in-Fact
Date
2026-11-13

Company context

Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com. Septerna intends to use its Investor Relations website and LinkedIn as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Septerna’s Investor Relations website and follow https://www.linkedin.com/company/septernainc on LinkedIn, in addition to following Septerna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Current securities

Recent company filings

  1. 4 filingNov 18, 2026
  2. 144 filingNov 16, 2026
  3. SCHEDULE 13G/A - filed by Third Rock Ventures V, L.P. regarding Septerna, Inc.Nov 16, 2026
  4. 144 filingNov 12, 2026
  5. 144 filingNov 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.